Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||
| Net Income | -746 | -297 | -778 |
| Other Working Capital | 250 | 7 | 42 |
| Other Operating Activity | 49 | 27 | 108 |
| Operating Cash Flow | $-447 | $-263 | $-628 |
| Cash Flows From Investing Activities | |||
| Investing Cash Flow | $N/A | $N/A | $0 |
| Cash Flows From Financing Activities | |||
| Debt Issued | 100 | N/A | N/A |
| Other Financing Activity | 0 | 0 | 1,032 |
| Financing Cash Flow | $100 | $N/A | $1,032 |
| Beginning Cash Position | 411 | 411 | 6 |
| End Cash Position | 63 | 147 | 410 |
| Net Cash Flow | $-347 | $-263 | $404 |
| Free Cash Flow | |||
| Operating Cash Flow | -447 | -263 | -628 |
| Free Cash Flow | -447 | -263 | -628 |